Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 28, 2021; 27(48): 8201-8215
Published online Dec 28, 2021. doi: 10.3748/wjg.v27.i48.8201
Published online Dec 28, 2021. doi: 10.3748/wjg.v27.i48.8201
Palmitoylation in Crohn’s disease: Current status and future directions
Wei-Xin Cheng, Yue Ren, Miao-Miao Lu, Ling-Ling Xu, Jian-Guo Gao, Farhin Shaheed Kalyani, Chun-Xiao Chen, Feng Ji, Xi Jin, Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Dong Chen, Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Zi-Yan Lv, Wenzhou Medical University Renji College, Wenzhou 325035, Zhejiang Province, China
He-Ning Lin, Department of Chemistry and Chemical Biology, Howard Hughes Medical Institute, Cornell University, Ithaca, NY 14853, United States
Author contributions: Cheng WX, Ren Y, Lu MM, Xu LL, Gao JG, Chen D, and Lv ZY conducted the literature review and wrote the section on Crohn’s disease; Lin H conceived and wrote the section on palmitoylation; Kalyani FS assisted with the writing and edited the review for language; Chen CX and Ji F conceived the review of the topic of Crohn’s disease and assisted with the literature review; Jin X conceived the overall concept of the review and supervised the research and writing processes.
Supported by National Science Foundation of China , No. 81770574 ; and Zhejiang Provincial National Science Foundation , No. LZ21H030002 .
Conflict-of-interest statement: Lin H is founder and consultant for Sedec Therapeutics. All other authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xi Jin, PhD, Professor, Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. jxfl007@zju.edu.cn
Received: March 19, 2021
Peer-review started: March 19, 2021
First decision: May 1, 2021
Revised: May 8, 2021
Accepted: December 2, 2021
Article in press: December 2, 2021
Published online: December 28, 2021
Peer-review started: March 19, 2021
First decision: May 1, 2021
Revised: May 8, 2021
Accepted: December 2, 2021
Article in press: December 2, 2021
Published online: December 28, 2021
Core Tip
Core Tip: S-palmitoylation is one of the most common post-translational modifications in nature; however, its importance has been overlooked for decades. Crohn’s disease (CD) is an autoimmune disease characterized by chronic inflammation of the entire gastrointestinal tract, whose underlying mechanisms of action remain poorly understood. Recent studies have revealed a key role of S-palmitoylation in CD; therefore, there is a need to elucidate the relationship between CD and S-palmitoylation. This review summarizes the basic facts of S-palmitoylation and its potential effect on CD to provide novel insights into the pathogenesis and treatment of CD.